Jubilant Pharmova posts Q4FY23 consolidated loss at Rs. 97.84 Cr

The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023

Hikal posts FY23 PAT at Rs. 36 Cr

Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22

NATCO records FY23 PAT at Rs. 715.3 Cr

The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.

Kristin Judge Joins Emmes as Chief Growth Officer

Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22

Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239

Aurobindo Pharma Q4 FY23 PAT up at Rs. 506 Cr

US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore

Roquette, Beren Therapeutics join forces to advance cyclodextrin technologies

Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.

Sun Pharmaceutical Industries posts Q4 FY23 consolidated PAT at Rs. 2016.78 Cr

The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023

Eugia Pharma receives USFDA approval for Carboprost Tromethamine Injection

The product is expected to be launched in June 2023

Supriya Lifescience Limited appoints of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D